In children with autism, those who show cognitive improvement after an anti-inflammatory diet also have much larger drops in four key immune and metabolic markers compared to those who don’t improve, indicating their initial biological state may predict whether the diet will help.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether baseline levels of CXCL1, RANTES, IFN-γ, and TMAO consistently predict cognitive response to anti-inflammatory diets across multiple studies in children with ASD.
A systematic review and meta-analysis of at least five RCTs or longitudinal cohorts measuring pre-intervention plasma biomarkers (CXCL1, RANTES, IFN-γ, TMAO) and post-intervention cognitive change in children with ASD, using standardized responder definitions (e.g., ≥0.5 SD improvement) and adjusting for age, sex, and baseline cognition.
Whether baseline immunometabolic profiles can prospectively identify children with ASD who will respond to an anti-inflammatory diet with cognitive improvement.
A prospective RCT with 200 children with ASD, stratifying participants into high/low biomarker groups (CXCL1, RANTES, IFN-γ, TMAO) at baseline, then randomizing all to anti-inflammatory diet or control, measuring cognitive change as primary outcome to test if baseline profile predicts response.
Whether baseline CXCL1, RANTES, IFN-γ, and TMAO levels predict future cognitive response to dietary interventions in children with ASD over time.
A prospective cohort study following 300 children with ASD for 24 months, measuring baseline biomarkers and cognitive performance, then documenting dietary exposure and cognitive change quarterly, using survival analysis to model time-to-response based on baseline profiles.
Whether children with ASD who respond to dietary intervention have distinct baseline immunometabolic profiles compared to non-responders.
A case-control study comparing 60 responders (≥0.5 SD cognitive improvement) to 60 non-responders matched for age, sex, and baseline cognition, analyzing pre-intervention plasma biomarkers, gut microbiota, and dietary intake patterns.
Whether baseline levels of CXCL1, RANTES, IFN-γ, and TMAO are associated with current cognitive performance in children with ASD.
A cross-sectional analysis of 250 children with ASD, measuring baseline biomarkers and cognitive performance at one time point, adjusting for age, sex, and medication, to assess if biomarker levels correlate with current cognitive status.